Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy.
adjuvants
cancer immunotherapy
helical virions
icosahedral virions
plant viruses
structurally modified virions
vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
16 Aug 2023
16 Aug 2023
Historique:
received:
13
07
2023
revised:
11
08
2023
accepted:
14
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
Vaccines are the cornerstone of infectious disease control and prevention. The outbreak of SARS-CoV-2 has confirmed the urgent need for a new approach to the design of novel vaccines. Plant viruses and their derivatives are being used increasingly for the development of new medical and biotechnological applications, and this is reflected in a number of preclinical and clinical studies. Plant viruses have a unique combination of features (biosafety, low reactogenicity, inexpensiveness and ease of production, etc.), which determine their potential. This review presents the latest data on the use of plant viruses with different types of symmetry as vaccine components and adjuvants in cancer immunotherapy. The discussion concludes that the most promising approaches might be those that use structurally modified plant viruses (spherical particles) obtained from the Tobacco mosaic virus. These particles combine high adsorption properties (as a carrier) with strong immunogenicity, as has been confirmed using various antigens in animal models. According to current research, it is evident that plant viruses have great potential for application in the development of vaccines and in cancer immunotherapy.
Identifiants
pubmed: 37631940
pii: vaccines11081372
doi: 10.3390/vaccines11081372
pmc: PMC10458565
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Russian Science Foundation
ID : 23-74-01008
Références
Viruses. 2021 Mar 29;13(4):
pubmed: 33805417
Viruses. 2021 Aug 26;13(9):
pubmed: 34578279
Nat Nanotechnol. 2016 Mar;11(3):295-303
pubmed: 26689376
Virol J. 2016 Nov 29;13(1):196
pubmed: 27894314
ACS Omega. 2018 Apr 30;3(4):3702-3707
pubmed: 29732445
Biomaterials. 2021 Aug;275:120914
pubmed: 34126409
ACS Nano. 2020 Mar 24;14(3):2994-3003
pubmed: 32133838
J Virol. 2019 Oct 15;93(21):
pubmed: 31375592
Adv Drug Deliv Rev. 2019 May;145:119-129
pubmed: 30172923
Immunology. 2020 Feb;159(2):183-192
pubmed: 31630392
Pharmaceutics. 2022 Apr 06;14(4):
pubmed: 35456639
J Immunol. 2014 Feb 1;192(3):1071-8
pubmed: 24376264
Virology. 2007 Jun 20;363(1):59-68
pubmed: 17320136
Vaccine. 2021 Aug 16;39(35):4979-4987
pubmed: 34325930
Vaccine. 2015 Dec 16;33(51):7245-7253
pubmed: 26549362
J Control Release. 2007 Jul 16;120(1-2):41-50
pubmed: 17512998
Data Brief. 2018 Oct 26;21:1504-1507
pubmed: 30510980
J Biomol Struct Dyn. 2014;32(8):1193-201
pubmed: 24099636
Adv Funct Mater. 2020 Jul 2;30(27):
pubmed: 34366758
Virol J. 2012 Mar 27;9:75
pubmed: 22452850
Front Microbiol. 2022 Feb 28;13:845316
pubmed: 35295298
PLoS One. 2011;6(6):e21522
pubmed: 21747909
Biomedicines. 2017 Jul 30;5(3):
pubmed: 28758953
Nanomedicine. 2022 Aug;44:102584
pubmed: 35850421
BioDrugs. 2022 Sep;36(5):573-589
pubmed: 35821564
Vaccines (Basel). 2021 Jul 05;9(7):
pubmed: 34358160
PLoS One. 2019 Jun 4;14(6):e0215031
pubmed: 31163034
Mol Biotechnol. 2021 May;63(5):424-436
pubmed: 33649932
Vaccines (Basel). 2021 Nov 05;9(11):
pubmed: 34835218
Int J Mol Sci. 2023 Jan 12;24(2):
pubmed: 36675043
Expert Rev Vaccines. 2008 Feb;7(1):33-41
pubmed: 18251692
Cancers (Basel). 2019 Apr 10;11(4):
pubmed: 30974896
Biomacromolecules. 2022 Apr 11;23(4):1812-1825
pubmed: 35344365
Curr Top Microbiol Immunol. 2014;375:19-45
pubmed: 22038412
Vaccines (Basel). 2020 Jul 20;8(3):
pubmed: 32698532
Virology. 2014 Jan 20;449:163-73
pubmed: 24418549
J Mol Biol. 2012 Sep 14;422(2):263-73
pubmed: 22659319
Mol Pharm. 2018 Sep 4;15(9):3717-3722
pubmed: 29613803
Viral Immunol. 2016 Dec;29(10):557-564
pubmed: 27834623
Vaccines (Basel). 2021 Nov 17;9(11):
pubmed: 34835278
PLoS One. 2015 Nov 06;10(11):e0142415
pubmed: 26545232
Biomater Sci. 2020 Sep 30;8(19):5489-5503
pubmed: 32914796
Immunology. 2008 Jun;124(2):186-97
pubmed: 18070030
J Virol Methods. 2022 Feb;300:114372
pubmed: 34838537
Adv Ther (Weinh). 2019 May;2(5):
pubmed: 33969181
FEBS J. 2006 Jan;273(1):14-25
pubmed: 16367744
Vaccine. 2008 Jun 25;26(27-28):3395-403
pubmed: 18511159
Data Brief. 2018 Oct 12;21:742-745
pubmed: 30406165
Nanomedicine. 2018 Nov;14(8):2563-2574
pubmed: 30193813
Colloids Surf B Biointerfaces. 2015 May 1;129:130-6
pubmed: 25847457
J Am Chem Soc. 2019 Apr 24;141(16):6509-6518
pubmed: 30995022
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562450
Vaccines (Basel). 2020 Dec 30;9(1):
pubmed: 33396667
Expert Rev Vaccines. 2010 Aug;9(8):859-76
pubmed: 20673010
Annu Rev Virol. 2020 Sep 29;7(1):513-535
pubmed: 32520661
Nat Rev Immunol. 2009 Apr;9(4):287-93
pubmed: 19247370
Vaccine. 2018 Sep 18;36(39):5865-5871
pubmed: 30126674
Life (Basel). 2022 Jan 21;12(2):
pubmed: 35207444
Viruses. 2020 Feb 28;12(3):
pubmed: 32121192
Nanomedicine. 2013 Oct;9(7):839-48
pubmed: 23499666
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36460333
Hum Vaccin Immunother. 2021 Feb 1;17(2):560-565
pubmed: 32614657
Mol Pharm. 2018 Sep 4;15(9):3700-3716
pubmed: 29798673
Nanoscale. 2018 Jan 25;10(4):1667-1679
pubmed: 29231944
Plant Biotechnol J. 2008 Dec;6(9):930-40
pubmed: 19076615
Mol Pharm. 2023 Jan 2;20(1):500-507
pubmed: 36399598
ACS Nano. 2022 Nov 22;16(11):18315-18328
pubmed: 36264973
Plant Biotechnol J. 2010 Jun;8(5):607-19
pubmed: 20199612
Mater Adv. 2021 Mar 7;2(5):1644-1656
pubmed: 34368764
Vaccine. 2021 Sep 15;39(39):5513-5523
pubmed: 34454786
Arch Virol. 2016 Oct;161(10):2673-81
pubmed: 27395369
Regul Toxicol Pharmacol. 2018 Aug;97:127-133
pubmed: 29932979
Mol Pharm. 2022 Feb 7;19(2):592-601
pubmed: 34978197
Nano Lett. 2016 Mar 9;16(3):1826-32
pubmed: 26891174
Sci Rep. 2020 Jun 25;10(1):10365
pubmed: 32587281
Adv Sci (Weinh). 2019 Jun 19;6(16):1802281
pubmed: 31453050
Antiviral Res. 2017 Aug;144:27-33
pubmed: 28511994
Vaccine. 2022 Feb 11;40(7):977-987
pubmed: 35063285
ACS Biomater Sci Eng. 2022 Jun 13;8(6):2518-2525
pubmed: 35522951
Plant Biotechnol J. 2015 Oct;13(8):1121-35
pubmed: 26073158
Front Cell Infect Microbiol. 2020 Oct 26;10:545371
pubmed: 33194793
J Gen Virol. 2012 Feb;93(Pt 2):400-407
pubmed: 22049093
Biomed Res Int. 2019 Oct 29;2019:4630891
pubmed: 31781617
Vaccines (Basel). 2022 Nov 18;10(11):
pubmed: 36423056
Front Microbiol. 2022 Sep 09;13:1003969
pubmed: 36160184
Microsc Microanal. 2013 Aug;19(4):808-13
pubmed: 23659679
Vaccine. 2022 Mar 15;40(12):1864-1871
pubmed: 35153091
Front Immunol. 2022 Oct 07;13:1021500
pubmed: 36275772
Nanomedicine (Lond). 2021 Jan;16(2):97-107
pubmed: 33442986
Mol Pharm. 2022 May 2;19(5):1573-1585
pubmed: 35333531
Biomed Res Int. 2014;2014:785382
pubmed: 24745025